5 Billionaires Buy Small-Cap – Week of 8/6

Aspiring investors and financial enthusiasts alike are always keen to gain insights into the strategies of the world’s most successful investors. With their vast wealth and unparalleled experience, billionaire investors are often viewed as beacons of wisdom in the stock market. Today we’ll take a closer look at three stocks that have caught the attention of billionaire investors, offering a glimpse into their investment portfolios and potential opportunities for investors looking to follow in their footsteps.

Here are three stocks investment legends have been buying recently –

Inari Medical, Inc. – SYM: NARI
Recent Price: $64.86
Legends: Steven Cohen, Ray Dalio, Jim Simons
Description: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

===

P10, Inc. – SYM: PX
Recent Price: $12.04
Legends: Paul Tudor Jones, Jim Simons, Steven Cohen
Description: P10, Inc., together with its subsidiaries, operates as a multi-asset class private market solutions provider in the alternative asset management industry in the United States. The company offers private equity, venture capital, impact investing, and private credit services, as well as primary fund of funds, secondary investment, and direct and co-investments services. It also provides tax credit transaction and consulting services. The company was founded in 1992 and is headquartered in Dallas, Texas.

===

LeMaitre Vascular, Inc. – SYM: LMAT
Recent Price: $57.60
Legends: Steven Cohen, Jim Simons, Ray Dalio
Description: LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient’s body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Categories

Recent posts

Tags

Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.